PATENT CLAIM ANALYSIS

Application Number: 16096830
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["548", "950000"]

Abstract:
Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.

Claim (Index 1):
A compound having formula (I): including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:\n A is selected from the group consisting of \n e is 1 or 2; g is 1, 2, or 3; n is 1 or 2; m is 1, 2, or 3; q is 1, 2, 3, 4, 5, or 6; R 1  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, optionally substituted aryl, C(O)R 2 , C(O)OR 3 , C(O)NR 4a R 4b , SO 2 R 5 , SO 2 NH 2 , and SO 2 NR 5a R 5b ; each occurrence of R 2  is independently selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; each occurrence of R 3  is independently selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; each occurrence of R 4a  is independently selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; each occurrence of R 4b  is independently selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; each occurrence of R 5  is independently selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; R 5a  is selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; R 5b  is selected from the group consisting of C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and optionally substituted aryl; R 6  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, C 3-7  cycloalkyl, and C(O)R 8 ; R 7a  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, C 1-6  linear alkoxy, C 3-7  branched alkoxy, and optionally substituted aryl; R 7b  is selected from the group consisting of hydrogen, C 1-6  linear alkoxy, C 3-7  branched alkoxy; R 7c  hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, and optionally substituted aryl; each occurrence of R 8  is independently selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, and C 3-7  cycloalkyl; R 9  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, C 1-6  linear alkoxy, C 3-7  branched alkoxy, optionally substituted aryl, NR 12a R 12b  NHC(O)R 13 , NHC(O)OR 13 , NHSO 2 R 5 , and NHSO 2 NH 2 ; R 10  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl; R 11a  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, C(O)R 2 , C(O)OR 3 , C(O)NR 4a R 4b , SO 2 R 5 , and SO 2 NH 2 ; R 11b  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl; or R 11a  and R 11b  may optionally be joined together with the atoms to which they are bound to form a ring containing 3, 4, or 5 atoms; or R 11a  and R 11b  may optionally be joined together with the atoms to which they are bound to form a ring containing 6 or 7 atoms, optionally containing an group selected from oxygen, sulfur and NR 14 ; each occurrence of R 12a  and R 12b  is independently selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl, or R 12a  and R 12b  may optionally be joined together with the atoms to which they are bound to form a ring containing 3, 4, 5, 6, or 7 atoms; each occurrence of R 13  is independently selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl; R 14  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl; X is selected from the group consisting of CR 15a R 15b  and NR 16 ; R 15a  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl NR 12a R 12b , NHC(O)R 13 , and NHC(O)OR 13 ; R 15b  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, and C 3-7  branched alkyl; R 16  is selected from the group consisting of hydrogen, C 1-6  linear alkyl, C 3-7  branched alkyl, optionally substituted aryl, optionally substituted benzyl, C(O)R 2 , C(O)OR 3 , C(O)NR 4a R 4b , SO 2 R 5 , and SO 2 NH 2 ; and R 17a  and R 17b  are at each occurrence independently selected from the group consisting of hydrogen and C 1-6  alkyl.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 97.0
- Lexical Diversity: 1.28571
- Patent Class: 548.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14895681', '14781081', '14388175', '15873293', '14412050']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7460642198901464
- 35 USC 102 Novelty (BERT): 0.5636246175403602
- Combined Prediction Score: 0.7278202596551678
- Mean Citation Score: 304.931952
- Max Citation Score: 425.56122
- Similarity Product: 404.7661877218223

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test